Pd173955
| Title | Journal |
|---|---|
| Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3. | Journal of medicinal chemistry 20131024 |
| Comprehensive analysis of kinase inhibitor selectivity. | Nature biotechnology 20111030 |
| Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. | Chemistry & biology 20101124 |
| New effective inhibitors of the Abelson kinase. | Bioorganic & medicinal chemistry 20100901 |
| A bead-based activity screen for small-molecule inhibitors of signal transduction in chronic myelogenous leukemia cells. | Molecular cancer therapeutics 20100501 |
| Induced disorder in protein-ligand complexes as a drug-design strategy. | Molecular pharmaceutics 20080101 |
| Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling. | Journal of medicinal chemistry 20060921 |
| Phosphorylation of IkappaB-beta is necessary for neuronal survival. | The Journal of biological chemistry 20060120 |
| Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. | Blood 20041015 |
| Direct evidence that Bcr-Abl tyrosine kinase activity disrupts normal synergistic interactions between Kit ligand and cytokines in primary primitive progenitor cells. | Molecular cancer research : MCR 20030101 |
| Src activation regulates anoikis in human colon tumor cell lines. | Oncogene 20021107 |
| Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). | Cancer research 20020801 |
| Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. | Cancer research 20020801 |